MEITAV INVESTMENT HOUSE LTD - UROGEN PHARMA LTD ownership

UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 65 filers reported holding UROGEN PHARMA LTD in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
MEITAV INVESTMENT HOUSE LTD ownership history of UROGEN PHARMA LTD
ValueSharesWeighting
Q3 2023$1,294,888
-41.4%
91,456
-56.7%
0.02%
+16.7%
Q2 2023$2,210,836
+76.7%
211,024
+96.8%
0.02%
-18.2%
Q1 2023$1,251,488
+5.7%
107,212
-21.6%
0.02%
+10.0%
Q4 2022$1,183,934
+4.5%
136,8350.0%0.02%0.0%
Q3 2022$1,133,000
+1.1%
136,8350.0%0.02%
+5.3%
Q2 2022$1,121,000
-6.0%
136,8350.0%0.02%
+5.6%
Q1 2022$1,192,000
-20.3%
136,835
-12.4%
0.02%
-25.0%
Q4 2021$1,495,000
-29.8%
156,186
+23.4%
0.02%
-31.4%
Q3 2021$2,129,000
-30.7%
126,590
-37.0%
0.04%
-10.3%
Q2 2021$3,070,000
+149.0%
201,038
+217.7%
0.04%
+11.4%
Q1 2021$1,233,000
+32.0%
63,280
+30.7%
0.04%
-23.9%
Q3 2020$934,000
-17.2%
48,407
+11.9%
0.05%
-31.3%
Q2 2020$1,128,000
+107.4%
43,255
+42.3%
0.07%
+63.4%
Q1 2020$544,000
-94.0%
30,406
-88.8%
0.04%
-93.8%
Q4 2019$9,080,000
+43.9%
272,063
+9.4%
0.66%
+45.5%
Q3 2019$6,310,000
-68.9%
248,593
-56.0%
0.45%
-66.5%
Q2 2019$20,309,000
-2.8%
565,548
-0.1%
1.35%
+15.3%
Q1 2019$20,902,000
+16.0%
565,848
+35.2%
1.17%
+5.1%
Q4 2018$18,021,000
-35.2%
418,490
-28.4%
1.12%
-17.7%
Q3 2018$27,799,000
-7.2%
584,104
+14.7%
1.36%
+1.2%
Q2 2018$29,967,000
+34.8%
509,355
+13.9%
1.34%
+18.4%
Q1 2018$22,229,000
+44.7%
447,352
+8.3%
1.13%
+25.9%
Q4 2017$15,363,000412,8820.90%
Other shareholders
UROGEN PHARMA LTD shareholders Q4 2018
NameSharesValueWeighting ↓
ProQuest Associates IV LLC 789,297$39,275,00060.44%
Wildcat Capital Management, LLC 251,459$12,513,0009.57%
Consonance Capital Management LP 1,487,491$74,018,0004.77%
MENORA MIVTACHIM HOLDINGS LTD. 2,499,870$124,394,0003.53%
MEITAV INVESTMENT HOUSE LTD 509,355$29,967,0001.34%
DSAM Partners (London) Ltd 127,588$6,349,0001.28%
SHIKIAR ASSET MANAGEMENT INC 48,125$2,395,0001.00%
BANK HAPOALIM BM 67,125$3,340,0000.91%
HIGHLINE CAPITAL MANAGEMENT, L.P. 331,900$16,515,0000.55%
Clal Insurance Enterprises Holdings Ltd 310,000$15,426,0000.40%
View complete list of UROGEN PHARMA LTD shareholders